Biogen's Litifilimab Shows Significant Efficacy in Second Positive Phase 2 Lupus Trial, Bolstering Breakthrough Status
BIIB sits 67% above its 52-week low of $110.035.
Summary
Biogen announced positive results from the Phase 2 AMETHYST study for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating a statistically significant 11.8% higher reduction in disease activity compared to placebo. This marks the second positive Phase 2 trial for litifilimab, consistent with the earlier LILAC study, and reinforces the drug's recently granted FDA Breakthrough Therapy Designation. The positive data de-risks a key pipeline asset for Biogen, as litifilimab targets a disease with significant unmet needs and no currently approved targeted therapies. Traders will be watching for the progression of the ongoing Phase 3 study, as successful development could open a new market for the company.
At the time of this announcement, BIIB was trading at $183.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.